According to a recent LinkedIn post from Parallel Fluidics, the company is emphasizing an automated approach to lipid nanoparticle, or LNP, formulation screening that integrates directly with existing liquid-handling systems. The post highlights a presentation by co-founder and CEO Joshua G. at the LNP Formulation Summit in Boston, where he reportedly showcased how this workflow operates in practice.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post suggests that Parallel Fluidics’ platform can generate more than 100 custom formulations per hour, which is described as about 10 times faster than some dedicated systems, while using minimal sample volumes. It also points to a focus on consistent, high-quality results using liquid handlers that labs already own, potentially lowering adoption friction for pharma, biotech, and mRNA developers.
The post also references a co-presentation with MilliporeSigma’s Jae Hyeon Park, hinting at engagement with a major life sciences supplier that could be relevant for validation, distribution, or co-marketing over time. For investors, if such performance metrics are borne out in commercial settings, this type of automation could strengthen Parallel Fluidics’ position in the LNP and mRNA tools market, support future revenue growth from platform deployments, and increase its strategic appeal to larger industry partners.